This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2011 Oct 31;10(11):798-800.

doi: 10.1038/nrd3581.

Buy buy bispecific antibodies

PMID: 22037028
DOI: 10.1038/nrd3581

Buy buy bispecific antibodies

David Holmes. Nat Rev Drug Discov. 2011.

. 2011 Oct 31;10(11):798-800.

doi: 10.1038/nrd3581.

Author

PMID: 22037028
DOI: 10.1038/nrd3581

No abstract available

PubMed Disclaimer

Similar articles

A bitter pill.
[No authors listed] [No authors listed] Nat Chem. 2010 May;2(5):337. doi: 10.1038/nchem.631. Nat Chem. 2010. PMID: 20414223 No abstract available.
To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M. Szpir M. Biotechniques. 2007 Apr;42(4 Suppl):S3-5. doi: 10.2144/000112432. Biotechniques. 2007. PMID: 18798735 No abstract available.
Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA, Feldman L, Seckler A, Wilson A. DiMasi JA, et al. Clin Pharmacol Ther. 2010 Mar;87(3):272-7. doi: 10.1038/clpt.2009.295. Epub 2010 Feb 3. Clin Pharmacol Ther. 2010. PMID: 20130567 Review.
Discontinued drugs in 2010: oncology drugs.
Williams R. Williams R. Expert Opin Investig Drugs. 2011 Nov;20(11):1479-96. doi: 10.1517/13543784.2011.623697. Epub 2011 Sep 28. Expert Opin Investig Drugs. 2011. PMID: 21955127
How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
Perakslis ED, Van Dam J, Szalma S. Perakslis ED, et al. Clin Pharmacol Ther. 2010 May;87(5):614-6. doi: 10.1038/clpt.2010.21. Epub 2010 Apr 7. Clin Pharmacol Ther. 2010. PMID: 20376001 Review. No abstract available.

See all similar articles

Cited by

DNA "nano-claw": logic-based autonomous cancer targeting and therapy.
You M, Peng L, Shao N, Zhang L, Qiu L, Cui C, Tan W. You M, et al. J Am Chem Soc. 2014 Jan 29;136(4):1256-9. doi: 10.1021/ja4114903. Epub 2014 Jan 13. J Am Chem Soc. 2014. PMID: 24367989 Free PMC article.
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.
Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Tustian AD, et al. MAbs. 2016 May-Jun;8(4):828-38. doi: 10.1080/19420862.2016.1160192. Epub 2016 Mar 10. MAbs. 2016. PMID: 26963837 Free PMC article.
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
Ruf P, Schäfer B, Eissler N, Mocikat R, Hess J, Plöscher M, Wosch S, Suckstorff I, Zehetmeier C, Lindhofer H. Ruf P, et al. J Transl Med. 2012 Nov 7;10:219. doi: 10.1186/1479-5876-10-219. J Transl Med. 2012. PMID: 23134699 Free PMC article.
A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis.
Kim Y, Yi H, Jung H, Rim YA, Park N, Kim J, Jung SM, Park SH, Park YW, Ju JH. Kim Y, et al. Sci Rep. 2016 Feb 4;6:20150. doi: 10.1038/srep20150. Sci Rep. 2016. PMID: 26841833 Free PMC article.
Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.
Kim CH, Axup JY, Dubrovska A, Kazane SA, Hutchins BA, Wold ED, Smider VV, Schultz PG. Kim CH, et al. J Am Chem Soc. 2012 Jun 20;134(24):9918-21. doi: 10.1021/ja303904e. Epub 2012 Jun 6. J Am Chem Soc. 2012. PMID: 22642368 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database